Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

4th Aug 2008 10:00

Notification of Acquisition of American Depository Shares by a Director/Person Discharging Managerial Responsibilities

Basingstoke, UK and Philadelphia, US - August 4, 2008 - Shire Limited , the global specialty biopharmaceutical company, announces that on August 1, 2008 the trustee of the Shire Employee Benefit Trust informed the Company that, on August 1, 2008, 6,471 American Depositary Shares in the Company ("ADSs") had been allocated under the Shire Executive Annual Incentive Plan (the "Plan") to Mr. Matthew Emmens. The ADSs were bought on the same date at a price of US$50.9298 per ADS. The allocation is in respect of the share based element of Mr. Emmens' 2008 pro-rated bonus which was based on his 2008 performance whilst Chief Executive Officer of the Company.

Under the terms of the Plan the ADSs will not normally be released to participants for three years.

The bonus was paid under Mr. Emmens' contract as Chief Executive Officer and represents his final bonus as Chief Executive Officer prior to him becoming Chairman on June 18, 2008.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

T May

Company Secretary

For further information please contact:

Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Notes to editorsSHIRE LIMITED

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

2

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

vendor

Related Shares:

Shire
FTSE 100 Latest
Value8,774.65
Change-17.15